Beren
110 employees on LinkedIn · 5 known investors
Find your way into Beren
1,787 people in our graph share verified history with the Beren team — schools, employers, funds. One of them is your warm intro.
Ken Chenaultunlockedknows Magali Hickey · together at Chief (overlapped)
×3knows the team · via The Wharton School
knows the team · via University of Washington
knows the team · via Moderna
knows the team · via Chief
×2knows the team · via Brandeis University
Beren is a public benefit corporation developing novel medicines in partnership with patients, caregivers, clinicians, and health systems. It focuses on advancing biology and chemistry to address the root causes of diseases.
Founders & leadership
JC
AO
Aaron OndreyinChief Financial Officer
AG
Alex GoldinChief Medical OfficerAlex Gold is a cardiologist and pharmaceutical executive with over 20 years of experience in drug development, clinical trials, and regulatory affairs across major biopharma companies. Harvard-trained and board-certified in cardiology and internal medicine, with Wharton management training, he has led clinical programs that advanced multiple marketed cardiovascular and metabolic therapies and managed regulatory interactions with the FDA, EMA, and other global authorities.
JS
Jennifer SpinellainChief Regulatory Officer & Head of QualityJennifer Spinella is Chief Regulatory Officer and Head of Quality at Beren, a public benefit corporation developing novel medicines in partnership with patients and health systems. She brings biotechnology industry experience in regulatory affairs.
IV
Irene von HennigsinSVP, Global Medical AffairsIrene von Hennigs is SVP of Global Medical Affairs at Beren. She has held senior medical strategy roles at both large and small pharmaceutical companies and has experience building teams and developing medical operational frameworks.
BS
Bennett SmithinSVP, CommercialBennett Smith spent over 20 years in pharma and biotech commercialization, holding roles supporting drug launches at Novo Nordisk, Akebia, and Regeneron before joining Beren as SVP of Commercial. He leads the company's integrated launch strategy across medical affairs, regulatory, finance, and supply chain functions.
RS
Rajinder SinghinChief Scientific Officer
MH
Magali HickeyinSVP, Technical Operations and CMCMagali Hickey is SVP of Technical Operations and CMC at Beren. She brings over 25 years of pharmaceutical and biotech experience, including roles advancing small molecules, biologics, and combination products from discovery through commercialization, and has overseen Chemistry, Manufacturing, and Controls strategies for global regulatory filings across vaccines, CNS, and oncology. She holds co-authorship on over 150 peer-reviewed publications and has contributed to the development of multiple marketed therapeutics.
HM
Heather McCueninChief People Officer
PC
Peter CicalainGeneral Counsel and Head of Intellectual Property and InnovationPeter Cicala has over ten years of experience as a medicinal chemist and has worked on drug development programs at major pharmaceutical companies and universities. As General Counsel at Beren, he brings expertise in pharmaceutical intellectual property, patent litigation, lifecycle management of therapeutics, and M&A transactions in the biotech industry.
Investors · 5
Competitors · 1
by search overlapCompanies competing with Beren for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Beren do?
- Beren is a public benefit corporation developing novel medicines in partnership with patients, caregivers, clinicians, and health systems. It focuses on advancing biology and chemistry to address the root causes of diseases.
- Who founded Beren?
- Beren was founded by Jason Camm.
- Who are Beren's investors?
- Beren's investors include Alpha Wave Global, Eisai Innovation, Inc., Narya Capital, Octave Ventures Llc, UTokyo Innovation Platform Co. Ltd..